| 2025-10-30 |
详情>>
股本变动：
变动后总股本6936.79万股
|
| 2025-10-30 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-2.87美元,归母净利润-1.99亿美元,同比去年增长-69.66%
|
| 2025-10-02 |
详情>>
内部人交易：
Skynner Michael等共交易13笔
|
| 2025-08-08 |
详情>>
业绩披露：
2025年中报每股收益-2.02美元,归母净利润-1.4亿美元,同比去年增长-110.48%
|
| 2025-05-01 |
详情>>
业绩披露：
2025年一季报每股收益-0.88美元,归母净利润-6075.4万美元,同比去年增长-128.72%
|
| 2025-04-23 |
股东大会：
将于2025-06-17召开股东大会
会议内容 ▼▲
- 1.To re-elect as a director Alessandro Riva, who retires in accordance with the Articles of Association.
2.To re-elect as a director Stephen Sands, who retires in accordance with the Articles of Association.
3.To approve, on advisory basis, the compensation of our named executive officers, as disclosed in this proxy statement.
4.To ratify the appointment of PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as our U.S. independent registered public accounting firm for the year ending December 31, 2025.
5.To re-appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as our U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders.
6.To authorize the Audit Committee to determine our U.K. statutory auditors’ remuneration for the year ending December 31, 2025.
7.To receive and adopt our U.K. statutory annual accounts and reports for the year ended December 31, 2024 (the “2024 U.K. Annual Report”).
8.To approve our directors’ remuneration report for the year ended December 31, 2024 (the “directors’ remuneration report”), which is set forth as Annex A to the attached proxy statement.
9.To approve an amendment to our Amended and Restated 2020 Equity Incentive Plan, which amendment is set forth as Annex C to the attached proxy statement.
|
| 2025-02-25 |
详情>>
业绩披露：
2022年年报每股收益-3.8美元,归母净利润-1.13亿美元,同比去年增长-68.69%
|
| 2025-02-25 |
详情>>
业绩披露：
2024年年报每股收益-2.9美元,归母净利润-1.69亿美元,同比去年增长6.44%
|
| 2024-10-31 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-2.15美元,归母净利润-1.17亿美元,同比去年增长10.94%
|
| 2024-08-06 |
详情>>
业绩披露：
2024年中报每股收益-1.4美元,归母净利润-6637.5万美元,同比去年增长18.72%
|
| 2024-08-06 |
详情>>
业绩披露：
2023年中报每股收益-2.71美元,归母净利润-8166.7万美元,同比去年增长-50.15%
|
| 2024-05-02 |
详情>>
业绩披露：
2024年一季报每股收益-0.62美元,归母净利润-2656.3万美元,同比去年增长32.00%
|
| 2024-04-15 |
股东大会：
将于2024-05-16召开股东大会
会议内容 ▼▲
- 1.To re-elect as a director Kevin Lee, who retires in accordance with the Articles of Association.
2.To re-elect as a director Jose-Carlos Gutierrez-Ramos, who retires in accordance with the Articles of Association.
3.To approve, on advisory basis, the compensation of our named executive officers, as disclosed in this proxy statement.
4.To ratify the appointment of PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as our U.S. independent registered public accounting firm for the year ending December 31, 2024.
5.To re-appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as our U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders.
6.To authorize the Audit Committee to determine our U.K. statutory auditors’ remuneration for the year ending December 31, 2024.
7.To receive and adopt our U.K. statutory annual accounts and reports for the year ended December 31, 2023 (the “2023 U.K. Annual Report”).
8.To approve our directors’ remuneration report for the year ended December 31, 2023 (the “directors’ remuneration report”), which is set forth as Annex A to the attached proxy statement.
9.To authorize the Board of Directors, generally and unconditionally for the purpose of section 551 of the U.K. Companies Act 2006 (the “Companies Act”) to allot shares in the company or to grant rights to subscribe for or to convert any security into shares in the company (“Rights”) up to a maximum aggregate nominal amount of ￡1,000,000. This authority shall expire (unless previously renewed, varied or revoked) on May 15, 2029, but we may at any time before the expiration of this authority make an offer or agreement which would or might require shares to be allotted, or Rights to be granted, pursuant to this authority after its expiration, and the Board of Directors may allot shares or grant Rights in pursuance of that offer or agreement as if the authority conferred by this resolution had not expired. The authority granted by this resolution shall replace all of our existing authorities to allot any shares and to grant Rights previously granted pursuant to section 551 of the Companies Act, but without prejudice to any allotment of shares or grant of Rights already made or agreed or offered to be made pursuant to such authorities.
10.Subject to the passing of Resolution 9, to empower the Board of Directors generally pursuant to section 570(1) and section 573 of the Companies Act to allot equity securities (as defined in section 560 of the Companies Act) for cash pursuant to the general authority conferred on them by Resolution 9 as if section 561(1) of the Companies Act did not apply to that allotment.
11.That with effect from the conclusion of the AGM, the draft articles of association, which are set forth as Annex B to the attached proxy statement, be adopted as the articles of association in substitution for, and to the exclusion of, our existing articles of association.
|
| 2024-02-20 |
详情>>
业绩披露：
2023年年报每股收益-5.08美元,归母净利润-1.81亿美元,同比去年增长-60.28%
|
| 2023-11-02 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-3.95美元,归母净利润-1.32亿美元,同比去年增长-59.01%
|
| 2023-04-28 |
股东大会：
将于2023-06-13召开股东大会
会议内容 ▼▲
- 1.To re-elect as a director Janice Bourque, who retires in accordance with the Articles of Association.
2.To re-elect as a director Veronica Jordan, who retires in accordance with the Articles of Association.
3.To re-elect as a director Sir Greg Winter, who retires in accordance with the Articles of Association.
4.To approve, on advisory basis, the compensation of our named executive officers, as disclosed in this proxy statement.
5.To ratify the appointment of PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as our U.S. independent registered public accounting firm for the year ending December 31, 2023.
6.To re-appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as our U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders.
7.To authorize the Audit Committee to determine our U.K. statutory auditors’ remuneration for the year ending December 31, 2023.
8.To receive and adopt our U.K. statutory annual accounts and reports for the year ended December 31, 2022 (the “2022 U.K. Annual Report”).
9.To approve our directors’ remuneration report for the year ended December 31, 2022 (the “directors’ remuneration report”), which is set forth as Annex A to the attached proxy statement (excluding the directors’ remuneration policy set out on pages A-3 to A-18 of the directors’ remuneration report and referenced in Proposal 10 below).
10.To approve the directors’ remuneration policy, which is set forth on pages A-3 to A-18 of Annex A to the attached proxy statement, which will take effect immediately after the end of the AGM.
|
| 2023-02-14 |
复牌提示：
2023-02-14 06:55:13 停牌，复牌日期 2023-02-14 09:50:00
|
| 2022-04-29 |
股东大会：
将于2022-06-27召开股东大会
会议内容 ▼▲
- 1.To re-elect as a director Pierre Legault, who retires in accordance with the Articles of Association.
2.To re-elect as a director Richard Kender, who retires in accordance with the Articles of Association.
3.To approve, on advisory basis, the compensation of our named executive officers, as disclosed in this proxy statement.
4.To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company’s named executive officers.
5.To approve the amendment of the Bicycle Therapeutics plc 2020 Equity Incentive Plan to increase the number of shares available for issuance under the plan.
6.To ratify the appointment of PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as our U.S. independent registered public accounting firm for the year ending December 31, 2022.
7.To re-appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as our U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders.
8.To authorize the Audit Committee to determine our U.K. statutory auditors’ remuneration for the year ending December 31, 2022.
9.To receive and adopt our U.K. statutory annual accounts and reports for the year ended December 31, 2021 (the “2021 U.K. Annual Report”).
10.To approve the directors’ remuneration report for the year ended December 31, 2021, which is set forth as Annex A to the attached proxy statement.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-30 |
股东大会：
将于2021-06-28召开股东大会
会议内容 ▼▲
- 1.To re-elect as a director Kevin Lee, who retires in accordance with the Articles of Association.
2.To re-elect as a director Jose Carlos Gutierrez-Ramos, who retires in accordance with the Articles of Association.
3.To ratify the appointment of PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as our U.S. independent registered public accounting firm for the year ending December 31, 2021.
4.To re-appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as our U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders.
5.To authorize the Audit Committee to determine our U.K. statutory auditors’ remuneration for the year ending December 31, 2021.
6.To receive and adopt our U.K. statutory annual accounts and reports for the year ended December 31, 2020 (the “2020 U.K. Annual Report”).
7.To approve the directors’ remuneration report for the year ended December 31, 2020 (excluding the directors’ remuneration policy set out on pages A-3 to A-15 of the directors’ remuneration report), which is set forth as Annex A to the attached proxy statement.
8.To authorize the Board of Directors, generally and unconditionally for the purpose of section 551 of the U.K. Companies Act 2006 (the “Companies Act”) to allot shares in the Company or to grant rights to subscribe for or to convert any security into shares in the Company (“Rights”) up to a maximum aggregate nominal amount of ￡250,000.00. This authority shall expire (unless previously renewed, varied or revoked) on June 27, 2026, but the Company may at any time before the expiration of this authority make an offer or agreement which would or might require shares to be allotted, or Rights to be granted, pursuant to this authority after its expiration, and the Board of Directors may allot shares or grant Rights in pursuance of that offer or agreement as if the authority conferred by this resolution had not expired. The authority granted by this resolution shall replace all existing authorities to allot any shares of the Company and to grant Rights previously granted pursuant to section 551 of the Companies Act, but without prejudice to any allotment of shares or grant of Rights already made or agreed or offered to be made pursuant to such authorities.
9.Subject to the passing of Resolution 8, to empower the Board of Directors generally pursuant to section 570(1) and section 573 of the Companies Act to allot equity securities (as defined in section 560 of the Companies Act) for cash pursuant to the general authority conferred on them by Resolution 8 as if section 561(1) of the Companies Act did not apply to that allotment. This power:
(a) shall be limited to the allotment of equity securities up to a maximum aggregate nominal amount of ￡250,000.00;
(b) expires (unless previously renewed, varied or revoked) on June 27, 2026, but the Company may at any time before the expiration of this authority make an offer or agreement which would or might require equity securities to be allotted after that expiry and the Board of Directors may allot equity securities pursuant to any of those offers or agreements as if this power had not expired;
(c) applies in relation to a sale of shares which is an allotment of equity securities by virtue of section 560(3) of the Companies Act as if in the first paragraph of this resolution the words “pursuant to the general authority conferred on them by Resolution 8” were omitted.
|
| 2020-04-27 |
股东大会：
将于2020-06-29召开股东大会
会议内容 ▼▲
- 1.To re-elect as a director Janice Bourque, who retires in accordance with the Articles of Association.
2.To re-elect as a director Veronica Jordan, who retires in accordance with the Articles of Association.
3.To re-elect as a director Sir Greg Winter, who retires in accordance with the Articles of Association.
4.To ratify the appointment of PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as our U.S. independent registered public accounting firm for the year ending December 31, 2020.
5.To re-appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as our U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders.
6.To authorize the Audit Committee to determine our U.K. statutory auditors' remuneration for the year ending December 31, 2020.
7.To receive and adopt our U.K. statutory annual accounts and reports for the year ended December 31, 2019 (the "2019 U.K. Annual Report").
8.To approve the directors' remuneration report for the year ended December 31, 2019 (excluding the directors' remuneration policy set out on pages A-4 to A-19 of the directors' remuneration report), which is set forth as Annex A to the attached proxy statement.
9.To approve the directors' remuneration policy, which is set forth on pages A-4 to A-19 of Annex A to the attached proxy statement, which will take effect immediately after the end of the AGM.
10.To approve our 2020 Equity Incentive Plan, which is set forth as Annex B to the attached proxy statement.
|